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Abstract 
Introduction: Despite the opioid epidemic adversely affecting areas across the U.S. for more than two 
decades and increasing evidence that medication-assisted treatment (MAT) is effective for patients with 
opioid use disorder (OUD), access to treatment is still limited. The limited access to treatment holds true 
in the Appalachia region despite being disproportionately affected by the crisis, particularly in rural, 
central Appalachia. 
Purpose: This research identifies opportunities for health centers located in high-need areas based on 
drug poisoning mortality to better meet MAT care gaps. We also provide an in-depth look at health center 
MAT capacity relative to need in the Appalachia region. 
Methods: The analysis included county-level drug poisoning mortality data (2013–2015) from the 
National Center for Health Statistics (NCHS)and Health Center Program Awardee and Look-Alike data 
(2017) on the number of providers with a DATA waiver to provide medication-assisted treatment (MAT) 
and the number of patients receiving MAT for the U.S. Several geospatial methods were used including an 
Empirical Bayes approach to estimate drug poisoning mortality, excess risk maps to identify outliers, and 
the Local Moran’s I tool to identify clusters of high drug poisoning mortality counties. 
Results: High-need counties were disproportionately located in the Appalachia region. More than 6 in 10 
health centers in high-need counties have the potential to expand MAT delivery to patients. 
Implications: The results indicate an opportunity to increase health center capacity for providing 
treatment for opioid use disorder in high-need areas, particularly in central and northern Appalachia. 
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Introduction 
Despite the opioid epidemic adversely affecting areas across the U.S. for more than two decades1 and 
increasing evidence that medication-assisted treatment (MAT) is effective for patients with opioid use 
disorder (OUD), access to treatment is still limited.2 The lack of access to treatment holds true in the 
Appalachia region, despite the region having been disproportionately affected by the crisis, particularly 
in rural, central Appalachia.3 While the opioid epidemic is a primary contributor to higher mortality rates 
in Appalachia,4-5 improving access to comprehensive health care and evidence-based treatments (such 
as MAT) have been identified as ways for addressing the opioid crisis in the region.6 
Health Resources and Services Administration (HRSA)-funded health centers and Health Center Program 
Look-Alikes were included in this analysis to explore ways to better address a growing OUD care need. 
HRSA-funded health centers are community-based and patient-directed organizations receiving funding 
through Section 330 of the Public Health Service Act. Health Center Look-Alikes do not receive Health 
Center Program funding but operate and provide services consistent with the Health Center Program 
requirements.7 Both HRSA-funded health centers and look-alikes (henceforth referred to as health 
centers) provide comprehensive primary care services in underserved areas and integrate access to 
pharmacy, mental health, substance use disorder, and oral health services in areas where economic, 
geographic, or cultural barriers limit access to affordable health care services.8   
With 1,373 health centers serving more than 27 million patients in 2017, health centers are 
fundamentally and geographically well-positioned to address the lack of access to treatment, as they 
focus on vulnerable populations and integrating access to primary care, pharmacy, mental health, and 
substance abuse services. Many health centers have Drug Addiction Treatment Act (DATA)-waived 
providers, who are licensed to prescribe buprenorphine as part of MAT (henceforth referred to as health 
center MAT capacity).9 However, research is needed to better understand current health center MAT 
capacity in high-need areas. This research identifies health centers located in high-need areas based on 
drug poisoning mortality and explores their capacity to provide MAT. We also provide an in-depth look 
at the Appalachia region and the capacity of health centers to provide MAT in high-need areas within 
Appalachia. 
Methods  
The analysis included county-level drug poisoning mortality data (2013-2015) from the National Center 
for Health Statistics (NCHS),10 county economic status data from the Appalachian Regional Commission 
(ARC, FY2019),11 and Health Center Program Awardee and Look-Alike data (2017 Uniform Data System)12 
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on the number of providers with a DATA waiver to provide medication-assisted treatment (MAT) and 
the number of patients receiving MAT9 as a proxy for capacity to provide OUD care.  
All participating organizations of the Health Center Program are required to report standardized annual 
data to HRSA through the Uniform Data System (UDS). Included in the UDS are data on patient 
demographics, performance in clinical quality measures, staffing and service utilization, and financial 
data, as well as the number of physicians, certified nurse practitioners, and physician assistants, on-site 
or with whom the health center has contracts, that have obtained a DATA waiver to treat opioid use 
disorders with medications approved by the U.S. Food and Drug Administration. Health centers also 
report the number of patients that received MAT for opioid use disorder from one of these providers. It 
is important to note that health center data are reported at the administrative level, meaning while 
each of the health centers may have multiple health center delivery sites, we are only mapping the 
administrative locations (which often serve as health center delivery sites as well).  
High-need counties were defined based on drug poisoning mortality (ICD-10 Codes – X40-X44, X60-X64, 
Y10-Y14) using GeoDa software13 and involved multiple steps, including the following:  first, counties 
with zero deaths were removed from the analysis; next, estimates of drug poisoning mortality death 
rates were created using an Empirical Bayes (EB) approach, which adjusts rates based on population 
numbers towards the overall mean (counties with small populations are adjusted more); next, excess 
risk maps were created to identify counties with adjusted drug poisoning death rates 1.5 times the 
national average; finally, the Local Moran’s I tool was used to identify statistically significant clusters of 
counties (hot spots) with high adjusted rates of drug poisoning mortality.13 A county was defined as 
high-need if it has a drug poisoning mortality excess risk of 1.5 times the national average or is part of 
drug poisoning mortality hot spot.  
After identifying high-need counties, health centers were mapped and stratified by current and 
potential capacity for MAT (based on their number of DATA waived providers and patients receiving 
MAT). Current and potential health center capacity was explored based on their number of DATA-
waived providers and number of patients receiving MAT. Health centers with at least one DATA-waived 
provider but had no patients receiving MAT were also highlighted. Note that health center MAT capacity 
is defined by the number of providers with a DATA waiver to prescribe buprenorphine as a part of MAT 
and does not include health centers that only provide other kinds of medications as part of MAT (i.e., 
naltrexone and methadone). 
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Results  
Figure 1 displays the 368 high-need counties, which have significantly higher drug poisoning mortality 
rates than non-high-need counties (25.8 per 100,000 vs. 15.2 per 100,000) and are clustered in several 
areas across the U.S. The darker colored counties (which meet both criteria of excess risk and hot spot) 
are usually the central counties in large high drug poisoning mortality clusters. Most high-need counties 
have at least one health center with MAT capacity, though this varies by geography with a lack of health 
center MAT capacity in some areas, including parts of the southwestern U.S. and Appalachia.  
About one-fifth (19.6%) of all 1,429 health centers are located in high-need counties, with a little more 
than one-half (55.5%) of these having at least one provider with a DATA-waiver, and 44.1% having 
patients utilizing MAT. More than one-fifth of the health centers with at least one DATA-waived provider 
do not have any patients utilizing MAT.  
Consistent with literature documenting higher rates of mortality in Appalachia, Figure 1 shows that high-
need counties are disproportionately located (40% of all high-need, 35% of all Appalachia counties) in 
the Appalachia region, including more than half of all counties that were identified as both drug 
poisoning mortality excess risk and hot spots. The largest number of high-need counties are in Central 
Appalachia (43.2% of high-need counties, 78.0% of all counties located in Central Appalachia), though 
many are also located in North Central and Northern Appalachia (39.2%). High-need Appalachia counties 
are also more likely to have an economic status of distressed, defined by the ARC as counties in the 
bottom quintile based on a composite measure of unemployment, per capita income, and poverty.11 
Compared to nationally, a lower proportion of the 137 health centers located in Appalachia are 
providing MAT, where more than 6 in 10 (63.5%) have no DATA-waived provider and more than 7 in 10 
(70.8%) have no MAT patients, compared to 58.9% and 67.0% for the U.S., respectively. There are 151 
DATA-Waived providers in 50 health centers in Appalachia serving 4,440 MAT patients. Almost one-half 
of health centers in Appalachia are located in high-need counties. More than one-half (54.4%) of these 
health centers have no MAT providers and more than 6 in 10 (61.7%) did not report providing MAT to its 
patients. More than 3,000 MAT patients are being seen by 96 DATA-waived providers at 31 health 
centers in high-need counties. 
Implications 
The results indicate an opportunity to increase health center capacity for providing treatment for OUD 
in the Appalachia region. For example, health centers in high-need counties that did not indicate MAT 
21
Topmiller et al.: Improving Access to Treatment for Opioid Use Disorder
Published by the University of Kentucky, 2020
capacity at the time the data were reported could be targeted for future outreach and resource 
allocation to increase number of DATA-waived providers; while health centers with MAT capacity but no 
MAT patients could be targeted for research and funding to identify reasons current DATA-waived 
providers are not providing MAT and provide incentives for treating more patients. This additional 
funding and research should also address the role of stigma in reducing access to treatment.14 As health 
centers already play an important role in improving access to health care in the Appalachia region, 
improving their capacity to deliver MAT could have a major impact in alleviating the opioid crisis. 
Indeed, increasing access to evidence-based treatment is one of recommendations of several reports 
focused on Appalachia, along with expanding telehealth services for treatment of opioid use disorder, 
which is another area health centers are well-suited to contribute.6  
 
While the intent of this research is to identify opportunities to better respond to opioid use disorder in 
Appalachia by leveraging health centers’ capacity, it has limitations related to data availability. First, 
high-need counties were defined using drug-poisoning mortality, which includes non-opioid drugs.  
Second, the mapping exercise included health centers as opposed to health center delivery sites. A 
health center entity can have multiple delivery sites, which can be located in different counties, and it is 
not possible to determine at which sites MAT is delivered since data in the UDS are reported at the 
parent/network organization level. Not including delivery sites in the analysis likely leads to an 
underestimation of health center capacity in the region. A third, related limitation is that we explored 
health center capacity in Appalachia focusing only on health centers located within Appalachia and did 
not include health centers that were located outside of Appalachia but had delivery sites within 
Appalachia. An additional limitation that may have led to underestimating health center capacity is that 
data for health centers providing MAT using naltrexone or methadone are not available.15 Finally, data 
for other providers unaffiliated with HRSA health centers were not included in this analysis. These non-
health center MAT providers may introduce competitive market forces and present barriers for health 
centers from entering the service area. Future research should look to incorporate state/local opioid-
specific mortality data along with more detailed data on MAT providers (both from health center 
delivery sites and other DATA-waived providers) in the region.  
 
Summary Box 
Despite the opioid epidemic adversely affecting areas across the U.S. including Appalachia and 
increasing evidence that medication-assisted treatment (MAT) is effective for patients with opioid use 
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disorder (OUD), access to treatment is still limited. Health centers are well-positioned to address opioid 
epidemic, but health centers in high-need areas, particularly in Central Appalachia, lack treatment 
capacity. This research identifies priority health centers that could be targeted for expanded resources 
to improve MAT capacity in high-need counties in Appalachia. 
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